The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...

Financial giants have made a conspicuous bearish move on Amgen. Our analysis of options history for Amgen (NASDAQ:AMGN) revealed 19 unusual trades. Delving into the details, we found 26% of ...

Amgen (AMGN) ended the recent trading session at $314.38, demonstrating a -0.53% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 1.77%.

Whales with a lot of money to spend have taken a noticeably bullish stance on Amgen. Looking at options history for Amgen (NASDAQ:AMGN) we detected 14 trades. If we consider the specifics of each ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently established that Amgen’s biosimilar Pavblu violates key patents of Eylea. A U.S.

Am­gen has shared ad­di­tion­al Phase 3 da­ta for its rare dis­ease drug Up­liz­na in myas­the­nia gravis, bol­ster­ing the com­pa­ny’s case for la­bel ex­pan­sion be­fore a … ...

Credit: shutterstock / CGN089. Amgen’s Uplizna (inebilizumab-cdon) has shown sustained efficacy in a group of generalised myasthenia gravis (gMG) patients after 52 weeks in a Phase III trial. Results ...

Shares of Verizon and Amgen are retreating Wednesday morning, sending the Dow Jones Industrial Average into negative territory. Supported by world-class markets data from Dow Jones and FactSet ...

placebo. Also Read: Amgen Challenges Novo Nordisk’s Ozempic And Eli Lilly’s Zepbound As Its Monthly Weight Loss Drug MariTide Enters Two Late-Stage Trials In addition, IGNITE met the endpoint ...